Rocket Pharmaceuticals Inc (RCKT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2016||Independent Chairman of the Board|
|57||2014||President, Chief Executive Officer, Director|
|44||2018||Principal Financial Officer, Principal Accounting Officer, Controller|
|57||2007||Executive Vice President, Chief Medical Officer|
- BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102
- BRIEF-Rocket Pharmaceuticals Announces Strategic Research Collaboration
- BRIEF-Rocket Pharma Appoints Former FDA Staffer As VP Of Regulatory Policy And Patient Advocacy
- BRIEF-Rocket Pharmaceuticals Reports Q1 Loss Per Share Of $0.42
- Rocket-control glitch delays launch of NASA's planet-hunting satellite